Company Profile
Veradigm Stock Price, News & Analysis
- Ticker:
- MDRX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
4.80 USD (0.00%)
Close
Last updated: August 6, 2026
—
Market cap
Why the stock is moving
As of Aug 6, 2026, MDRX was little changed and closed at $4.80. No new same-company headline was identified in the current news window.
Company overview
Business overview
Veradigm is a healthcare information and analytics company focused on software, data, and workflow tools for providers and life-sciences customers. Its business is more about information infrastructure than therapeutic innovation.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Veradigm sits in healthcare IT.
Business Model Characteristics
Revenue depends on software subscriptions, data products, and the commercialization of workflow tools across healthcare users.
Position Within the Biotechnology Landscape
Veradigm is outside biotech and belongs to the healthcare information layer, where software adoption and execution matter most.
Future catalysts
Veradigm's catalysts are claims-data products, payer and life-science software demand, and any operating update that clarifies the turnaround path. The company is still a software-and-data execution story.
Recent news
- 01
Veradigm Files 2023 and 2024 Form 10-K
Source: Veradigm
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Veradigm (MDRX)?
Veradigm (MDRX) most recently closed at 4.80 USD, a 0.00% move versus the previous session.
What does Veradigm do?
Veradigm is a healthcare information and analytics company focused on software, data, and workflow tools for providers and life-sciences customers. Its business is more about information infrastructure than therapeutic innovation.
On which exchange is MDRX stock listed?
Veradigm (MDRX) is associated with NASDAQ, United States, Biopharma.
What is Veradigm?
Veradigm's catalysts are claims-data products, payer and life-science software demand, and any operating update that clarifies the turnaround path.
Which conditions is Veradigm targeting with Veradigm?
Veradigm's catalysts are claims-data products, payer and life-science software demand, and any operating update that clarifies the turnaround path.
How does Veradigm describe recent progress with Veradigm?
Veradigm's catalysts are claims-data products, payer and life-science software demand, and any operating update that clarifies the turnaround path.
What future catalysts are investors watching for Veradigm?
Veradigm's catalysts are claims-data products, payer and life-science software demand, and any operating update that clarifies the turnaround path. The company is still a software-and-data execution story.